239 related articles for article (PubMed ID: 34330821)
1. Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss.
Pasquariello KZ; Dey JM; Sprowl JA
Mol Pharmacol; 2021 Oct; 100(4):348-355. PubMed ID: 34330821
[TBL] [Abstract][Full Text] [Related]
2. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
5. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010885. PubMed ID: 29975402
[TBL] [Abstract][Full Text] [Related]
6. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
8. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
9. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD010885. PubMed ID: 31961948
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.
Waissbluth S; Daniel SJ
Hear Res; 2013 May; 299():37-45. PubMed ID: 23467171
[TBL] [Abstract][Full Text] [Related]
11. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.
Schacht J; Talaska AE; Rybak LP
Anat Rec (Hoboken); 2012 Nov; 295(11):1837-50. PubMed ID: 23045231
[TBL] [Abstract][Full Text] [Related]
13. Prevention and restoration of hearing loss associated with the use of cisplatin.
Chirtes F; Albu S
Biomed Res Int; 2014; 2014():925485. PubMed ID: 25140325
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.
Selim MS; Kassem AB; El-Bassiouny NA; Salahuddin A; Abu El-Ela RY; Hamza MS
Med Oncol; 2023 Jan; 40(2):80. PubMed ID: 36650399
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide adenine dinucleotide: An essential factor in preserving hearing in cisplatin-induced ototoxicity.
Kim HJ; Oh GS; Shen A; Lee SB; Khadka D; Pandit A; Shim H; Yang SH; Cho EY; Song J; Kwak TH; Choe SK; Park R; So HS
Hear Res; 2015 Aug; 326():30-9. PubMed ID: 25891352
[TBL] [Abstract][Full Text] [Related]
17. Puerarin inhibits cisplatin-induced ototoxicity in mice through regulation of TRPV1-dependent calcium overload.
Lin Y; Liang R; Xie K; Ma T; Zhang J; Xu T; Wang A; Liu S
Biochem Pharmacol; 2024 Feb; 220():115962. PubMed ID: 38043717
[TBL] [Abstract][Full Text] [Related]
18. Review: ototoxic characteristics of platinum antitumor drugs.
Ding D; Allman BL; Salvi R
Anat Rec (Hoboken); 2012 Nov; 295(11):1851-67. PubMed ID: 23044998
[TBL] [Abstract][Full Text] [Related]
19. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
20. Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity.
Jamesdaniel S; Rathinam R; Neumann WL
Redox Biol; 2016 Dec; 10():257-265. PubMed ID: 27821327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
